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PhosphoinositidesADP plays critical signaling roles in the vascular endothelium. ADP receptors are targeted by several cardiovas-
cular drugs, yet the intracellular pathways modulated by ADP are incompletely understood. These studies
have identiﬁed important roles for the phosphatase PTEN in ADP-dependent modulation of the endothelial iso-
form of nitric oxide synthase (eNOS) as well as of lipid and protein kinase pathways in endothelial cells. We ﬁnd
that ADP-promoted eNOS activation as well as phosphorylation of p38 MAPK are enhanced by siRNA-mediated
PTEN knockdown. However, the increase in ADP-dependent eNOS activation promoted by PTEN knockdown is
abrogated by siRNA-mediated knockdown of p38 MAPK. These ﬁndings indicate that PTEN tonically suppresses
both p38 phosphorylation aswell as ADP-stimulated eNOS activity. A key enzymatic activity of PTEN is its role as
a lipid phosphatase, catalyzing the dephosphorylation of phosphoinositol-3,4,5-trisphosphate (PIP3) to
phosphoinositol-4,5-bisphosphate (PIP2).We performed biochemical analyses of cellular phospholipids in endo-
thelial cells to show that siRNA-mediated PTEN knockdown leads to a marked increase in PIP3. Because these
complex lipids activate the small GTPase Rac1, we explored the role of PTEN in ADP-modulated Rac1 activation.
We used a FRET biosensor for Rac1 to show that ADP-dependent Rac1 activation is blocked by siRNA-mediated
PTENknockdown.We then exploited a FRET biosensor for PIP3 to show that the strikingADP-dependent increase
in intracellular PIP3 is entirely blocked by PTEN knockdown. These studies identify a key role for PTEN in the
modulation of lipid mediators involved in ADP receptor-regulated endothelial signaling pathways involving
eNOS activation in vascular endothelial cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The nucleotide ADP plays a key role as an extracellular signaling mol-
ecule and binds to a family of G protein-coupled receptors that modulate
diverse biological processes including platelet aggregation, vascular tone,
and neurotransmission. ADP is released by red blood cells and by activat-
ed platelets in response to both physiological and pathophysiological
stimuli [1]. ADP receptor antagonists are widely used in cardiovascular
therapeutics [2], yet the pathways whereby extracellular ADP modulate
endothelial function are incompletely understood.We recently identiﬁed
some of the signaling pathways connecting P2Y1 ADP receptors with the
endothelial isoformof nitric oxide synthase (eNOS). Studies inbovine aor-
tic endothelial cells (BAEC) showed that P2Y1 is the principal purinergic
receptor subtype that mediates ADP signaling responses [3]. eNOS is aomas_michel@harvard.edu
l rights reserved.key determinant of vascular tone, and is dynamically regulated by a
broad range of cell surface receptors that elicit increases in intracellular
calcium levels. The enzymatic activity of eNOS is critically inﬂuenced by
enzyme phosphorylation at multiple serine, threonine, and tyrosine resi-
dues [4–6]. The protein kinase and phosphoprotein phosphatase path-
ways that regulate eNOS phosphorylation are complexly regulated; the
phosphatidylinositol 3-kinase (PI3K)/kinase Akt pathway has been clear-
ly implicated in eNOS signaling responses. ADP treatment of endothelial
cells promotes the receptor-dependent activation of numerousprotein ki-
nases, including the AMP-activated protein kinase. The eNOS phosphory-
lation pathways that are modulated by endothelial P2Y1 receptors for
ADP are particularly enigmatic: ADP-dependent eNOS activation requires
the expression but not the activity of several protein kinases in endothe-
lial cells [3]. Our search for other signaling pathways that might dynami-
cally regulate ADP-modulate eNOS phosphorylation led us to study the
lipid and protein phosphatase PTEN.
PTEN (“phosphatase and tensin homolog on chromosome 10”)
catalyzes the dephosphorylation of phospholipids as well as phos-
phoproteins (for reviews see refs. [7,8]). PTEN is the protein most
commonly mutated in human malignancies, and the regulation of
this key enzyme has been extensively analyzed in studies of cell
transformation. PTEN contains the signature sequence motif of the
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most cells are not phosphoproteins. Instead, the principal PTEN sub-
strate is the phospholipid second messenger phosphatidylinositol
3,4,5-trisphosphate (PIP3), which is dephosphorylated by PTEN to
yield phosphatidylinositol 4,5-bisphosphate (PIP2). Changes in the
levels of these complex lipids second messengers inﬂuence diverse
cellular pathways, including alterations in cell growth, differentia-
tion, apoptosis, metabolism, and motility [9,10]. These responses
are initiated by the binding of phosphoinositides to proteins that
possess highly speciﬁc phosphoinositide-binding pleckstrin homol-
ogy domains that selectively bind PIP3, PIP2, and other structurally
related bioactive complex lipids [11]. PTEN-mediated catabolism of
PIP3 to PIP2 antagonizes signaling through the PI3K pathway, with
important consequences for the phosphorylation of kinase Akt and
the regulation of eNOS [12]. PTENmodulates not only the abundance
of PIP3 but also the temporal and spatial distribution of this lipid and
related biologically active phosphoinositides [13]. PTEN is widely
distributed in mammalian tissues, and its enzymatic activity is con-
trolled both by reversible phosphorylation and by cellular redox
state [10,14,15]. An active interplay between phosphorylation and
redox pathways permits PTEN activity and targeting to be precisely
regulated within the cell. PTEN phosphorylation occurs on several
threonine and serine residues located in a polybasic domain in the
protein's C terminus, leading both to PTEN translocation as well as
a decrease in enzymatic activity. The protein kinase pathways that
modulate PTEN phosphorylation are less well understood and a con-
nection between ADP signaling and PTEN has not previously been
established. The phosphoprotein phosphatase substrates of PTEN in-
clude diverse protein kinases, including the focal adhesion kinase,
Shc [16–19], as well as p38 MAP kinase [20]. The reversible phos-
phorylation of p38 MAPK has been implicated in a broad range of in-
tracellular responses [21–23], including key roles in endothelial
signaling pathways [24].
These studies have explored the role of PTEN in ADP-modulated
eNOS activation in vascular endothelial cells. We exploited novel bio-
sensors and used both RNA interference and biochemical approaches
to provide evidence showing that PTEN is dynamically regulated by
ADP pathways in vascular endothelial cells. These studies help to es-
tablish a critical role for lipid second messengers in ADP-modulated
signaling to eNOS in the endothelium.
2. Materials and methods
2.1. Reagents
Fetal bovine serum (FBS) was purchased from HyClone Lab-
oratories (Logan, UT). All other cell culture reagents, media, and
Lipofectamine 2000 were from Invitrogen (San Diego, CA). PD169316
was from Calbiochem (San Diego, CA). PIP3 Grip was from Echelon
Bioscience (Salt Lake City, UT). Protease inhibitor cocktail tablets
were purchased from Roche (Indianapolis, IN). Polyclonal antibodies
against phospho-eNOS (Ser1177), p38 MAPK, PTEN, phospho-PTEN
(Ser380/Thr382/383), Akt, actin, and phospho-Akt (Ser473) were
from Cell Signaling (Danvers, MA). Monoclonal antibody phospho-
p38 MAPK (Thr180/Tyr182) was from Cell Signaling, monoclonal anti-
body against eNOS was from BD Transduction Laboratories (San Jose,
CA), and GST monoclonal antibody from GenScript (Piscataway, NJ).
SuperSignal chemiluminescence detection reagents and secondary an-
tibodies conjugated with horseradish peroxidase were from Pierce Bio-
technology. All other reagents were from Sigma-Aldrich (St. Louis,
MO).
2.2. Cell culture and transfection
BAECwere obtained fromGenlantis (SanDiego, CA) andmaintained
in culture in Dulbecco's modiﬁed Eagle's medium supplemented withfetal bovine serum (10%, v/v) as described [25]. Cells were plated onto
gelatin-coated culture dishes and studied prior to cell conﬂuence be-
tween passages 6 and 8. siRNA transfections were performed as de-
scribed previously [26]. BAEC were transfected with 30 nM siRNA
24 h after cells were split at a 1:8 ratio using Lipofectamine 2000
(0.15%, v/v), following the protocol provided by the manufacturer.
Lipofectamine 2000 was then removed by changing into fresh medium
containing 10% FBS 5 h after transfection.
2.3. siRNA preparation
Wedesigned small interfering RNAduplex oligonucleotides targeting
constructs, whichwere purchased fromAmbion. The following sense se-
quences were used: siRNA-p38, 5′-GGUCUCUGGAGGAAUUCAAtt-3′;
siRNA-PTEN, 5′-GUAUAGAGCGUGCAGAUAAtt-3′; and siRNA-Akt1, 5′-G
GA CGU GUA CGA GAA GAA GdTdT-3′.
2.4. Cell treatments and immunoblot analysis
Culturemediumwas changed to serum-freemedium overnight prior
to all experiments. ADP was dissolved in water and stored at −20 °C.
PD169316 was solubilized in dimethyl sulfoxide (DMSO) and stored in
the dark at −20 °C. Where indicated, dimethyl sulfoxide 0.1% (v/v)
was used as vehicle control. After drug treatments, BAEC were washed
with PBS and incubated for 20 min in lysis buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate,
1 mM EDTA, 2 mM Na3VO4, 1 mM NaF and protease inhibitor cocktail
tablets (following the instructions provided by the supplier). After cells
were harvested and lysed, immunoblot analyses of protein abundance
and phosphorylation were processed as previously described [27].
2.5. Lipid extraction
Cells cultured in 6-well plates were transfected as described above;
48 h after transfection, cells were scraped into 0.3 ml of 0.5 M sodium
carbonate, pH 11 and homogenized in a Dounce homogenizer followed
by sonication. After sonication, triplicate 50 μl aliquots were spotted on
a nitrocellulose membrane and dried; the membranes were washed
twice with PBS-5% Tween, blocked with PBS-3% BSA for 1 h at room
temperature, incubated with the GST-tagged “PIP3-Grip”, washed ex-
tensively, and detected using the GST antibody.
2.6. eNOS activity assay
eNOS activity was quantitated by measuring the formation of L-[3H]
citrulline from L-[3H]arginine as described previously [28]. The
basal eNOS activity in these experiments ranged from 0.3 to
0.7 pmol/mg protein/min. Brieﬂy, the reactionwas initiated in cultured
BAEC by adding L-[3H]arginine (10 μCi/ml, diluted with unlabeled
L-arginine to give a ﬁnal concentration of 10 μM) plus various drug
treatments. Each treatment was performed in triplicate cultures,
which were analyzed in duplicate.
2.7. Fluorescent resonance energy transfer (FRET) measurement
Monitoring of PIP3 production and Rac1 activation were performed
by the use of speciﬁc FRET biosensor probes, as described in detail [29].
Brieﬂy, the FRET biosensor for PIP3 consists of the PIP3 binding domain
ﬂanked by CFP and YFP sequences in a conformation that does not
allow FRET between the ﬂuorophores. When PIP3 accumulates in the
plasma membrane, the biosensor binds to PIP3, resulting in a conforma-
tional change that leads to an increase in FRET efﬁciency. BAEC were
transfected with duplex siRNA targeting constructs along with either
the PIP3 or Rac1 biosensor plasmids. 48 h after transfection, living cells
were imaged in an Olympus DSU ﬂuorescence microscope. Agonists
were added after 5 min, and ﬂuorescence images were captured every
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MetaMorph software (Universal Imaging, Downingtown, PA).
2.8. Confocal ﬂuorescence microscopy
BAEC were grown on glass Lab-Tek Chamber Slides and transfected
with control or PTEN siRNA. 48 h after transfection, cells were ﬁxed
with 4% paraformaldehyde in PBS for 20 min, permeabilized in 0.1% Tri-
ton X-100 for 15 min and blocked for 1 hwith 10% goat serum. After in-
cubation with vinculin antibody at 4 °C overnight (1:400), cells were
washed three times in PBS and incubated for 2 h with an Alexa Fluor
568 antibody (1:2000). For staining of F-actin, Alexa Fluor 488
phalloidin was incubated together with the secondary antibody. Fixed
cells were washed to remove excess antibody and mounted on slides,
which were examined using an Olympus DSU microscope; images
were analyzed using Metamorph software.Fig. 1. ADP-stimulated phosphorylation of PTEN and p38 MAPK. Lysates prepared from AD
shown. Panel A, time course of PTEN phosphorylation in endothelial cells treated with ADP
mined at t = 20 min) for ADP-stimulated p38 MAPK phosphorylation (pp38 MAPK). The b
equivalent results; the graphs next to each blot represent quantiﬁcation of pooled data.2.9. Scratch wound cell migration assay
BAEC were transfected with siRNA-targeting constructs and
grown for 24 h. Cells were added to each chamber of a 8-well cell
culture chamber slide (IBIDI, Munich, Germany) to adhere for 24 h
in Dulbecco's modiﬁed Eagle's mediumwith 1.0% FBS. The cell mono-
layer was scratched by a pipette tip and migration was recorded
using a 10X DIC objective on an inverted Olympus DSU microscope
for 30 h.2.10. Statistical analysis
In the experiments involving multiple comparisons, ANOVA
was used; a p value of less than 0.05 was considered statistically
signiﬁcant.P-treated endothelial cells were analyzed in immunoblots probed with antibodies as
(25 μM); panels B and C (respectively), show time course and dose response (deter-
lots shown are representative of at least three independent experiments that yielded
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3.1. ADP promotes reversible phosphorylation of PTEN and p38 MAPK in
endothelial cells
We ﬁrst explored the effect of ADP on the phosphorylation of PTEN
and related signaling proteins in cultured endothelial cells. As shown in
Fig. 1A, physiological concentrations of ADP promote the robust phos-
phorylation of PTEN; phosphorylation of PTEN is associatedwith inacti-
vation of its lipid phosphatase activity [9,15]. We next explored the
effects of ADP on phosphorylation of p38 MAP kinase (p38 MAPK)
(Fig. 1B and C), a phosphoprotein that modulates multiple signaling re-
sponses in these cells [30]. Aswe found for PTEN, ADP also induces a re-
versible phosphorylation of p38 at its activation site (Thr180/Tyr182).
3.2. ADP-mediated eNOS and p38MAPK activation are modulated by PTEN
PTEN is the principal negative regulator of PI3K/Akt pathway
[31,32], which in turn plays a key role in eNOS regulation [33–35].Fig. 2. Effects of siRNA-mediated PTEN knockdown on eNOS phosphorylation and enzyme activ
which endothelial lysates were prepared from control or PTEN siRNA-transfected cells that we
immunoblots as shown. Bar graph shows the mean ± SEM of four independent experiment
[3H]-arginine-[3H]-citrulline assay (as described in Materials and methods), as analyzed in P
20 min. Since the basal eNOS activity varied slightly from experiment to experiment, the data a
of ADP. The graph shows the mean ± s.e.m. of four independent experiments. * indicates p bWe designed and validated highly speciﬁc and potent duplex siRNA
targeting constructs for PTEN that yielded ~90% PTEN knockdown in
transfected endothelial cells, without affecting the abundance of
eNOS (Fig. 2A). As shown in Fig. 2A and B, siRNA-mediated PTEN
knockdown markedly increased basal as well as ADP-stimulated
eNOS phosphorylation at serine 1179 and led to an increase in basal
and ADP-stimulated eNOS activity. siRNA-mediated PTEN knockdown
also led to a marked increase in basal and ADP-stimulated p38 MAPK
phosphorylation (Fig. 2C).
3.3. p38 MAPK inhibition blocks ADP-dependent eNOS activation
We developed and validated a duplex siRNA targeting construct to
knock down p38 MAPK; this targeting construct promoted the potent
and speciﬁc knockdown of p38 MAPK in endothelial cells (Fig. 3A). Al-
though four different isoforms of p38 MAPK have been described in
mammals (α, β, γ and δ), the cardiovascular importance of p38α is
the best characterized [36–38]. As shown in Fig. 3A (lower panel),
siRNA-mediated p38 MAPK-knockdown markedly suppressed ADP-ity. Immunoblots in panels A and panel C show representative time course experiments in
re treated with ADP (25 μM) for the indicated times, and then probed with antibodies in
s. Panel B shows pooled data from four experiments measuring eNOS activity using the
TEN and control siRNA-transfected endothelial cells and treated with ADP or vehicle for
re normalized to the enzyme activity seen in control siRNA-transfected cells in the absence
0.05, ** indicates p b 0.01, and *** indicates p b 0.001.
Fig. 3. Effects of siRNA-mediated knockdown or pharmacological inhibition of p38 MAPK
on eNOS activity. In Panel A, endothelial cells transfectedwith control or p38MAPK siRNA
targeting constructswere treatedwith ADP (25 μM) for the indicated times. Equal loading
was assessed by immunoblotting with antibodies directed against total eNOS, p38 MAPK
and PTEN, and eNOS activity was measured using the [3H]-arginine-[3H]-citrulline assay.
Panel B shows the pooled results of eNOS activity assays analyzed in endothelial cells
treated with the p38 MAPK inhibitor PD169316 (10 μM) for 30 min and then treated
with ADP (25 μM) for 20 min. * indicates p b 0.05.
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permeable, competitive and selective p38 MAPK kinase inhibitor
PD169316 (Fig. 3B). The concordant effects of siRNA-mediated p38
MAPK knockdown and a p38 MAPK kinase inhibitor help to establish
p38 MAPK as an upstream kinase critically involved in ADP-mediated
eNOS activation.
3.4. Interactions between PTEN, p38 MAPK and kinase Akt in eNOS
activation
In order to explore the interplay between PTEN and p38 MAPK in
eNOS regulation, we performed “double knockdown” experiments
using two separate siRNA constructs to target PTEN and p38 MAPK. As
shown in Fig. 4A, siRNA-mediated p38 MAPK knockdown attenuated
the increase in eNOS enzyme activity and eNOS phosphorylation that
was observed following PTEN knockdown. Interestingly, the increase in
Akt phosphorylation that was seen after PTEN knockdown was further
enhanced by also knocking down p38 MAPK (Fig. 4A, right panel), indi-
cating possible interactions between these two kinase pathways. We
next explored the effect of siRNA-mediated knockdown of p38 MAPK
on PTEN inactivation by ADP. As shown in Fig. 4B, p38MAPK knockdown
led to an increase in PTEN inhibition, which correlated with an increase
in Akt activationmediated by ADP. These eventsmight explain the resid-
ual eNOS activity that is observed following p38 MAPK knockdown
(Fig. 3). We next performed double knockdown experiments with
targeting constructs for both PTEN and Akt. As shown in Fig. 4C,
siRNA-mediated Akt knockdown partially blocked ADP-stimulated
eNOS activity, yet additional siRNA-mediated knockdown of PTEN par-
tially recovered the eNOS response to ADP.
3.5. PTEN knockdown blocks ADP-mediated PIP3 generation
To study the inhibitory effect of ADP on PTEN activity and PIP3
levels, we performed live cell imaging experiments. We transfected
endothelial cells with control or PTEN siRNA, and determined cellular
PIP3 content using a biochemical assay for PIP3. As expected, since
PTEN is the main phosphoinositide phosphatase that metabolizes
PIP3 [13], siRNA-mediated PTEN knockdown led to a signiﬁcant in-
crease in cellular PIP3 levels (Fig. 5A). We next performed live cell im-
aging experiments using a highly speciﬁc FRET biosensor [29] to
measure the dynamics of ADP-modulated changes in PIP3 following
siRNA-mediated PTEN knockdown. We co-transfected endothelial
cells with the PIP3 biosensor along with either control or PTEN
siRNA, and then analyzed dynamic FRET responses in live cells follow-
ing addition of ADP. In control siRNA-treated cells, ADP treatment
stimulated a marked rise in the FRET signal from the PIP3 biosensor,
reﬂecting a dynamic increase in PIP3 levels along endothelial cell plas-
matic membranes following agonist treatment. By contrast, following
siRNA-mediated PTEN knockdown, the ADP-promoted increase in
FRET from the PIP3 biosensor was no longer observed (Fig. 5B).
Since live cell imaging using the FRET biosensor can only detect
changes in PIP3 abundance but not the absolute levels of intracellular
PIP3, FRET data were normalized to the basal CFP/YFP ratio in each
condition (Fig. 5C), indicating that PTEN knockdown effectively sup-
presses any further increase in PIP3 after addition of ADP, consistent
with the effect of ADP on inactivation of PTEN.
3.6. PTEN regulates endothelial cell migration, actin organization and
Rac1 activation
Given the involvement of ADP in PTEN regulation, we next ana-
lyzed the functional consequences of PTEN inactivation on endotheli-
al function. It has been previously described that the complex lipid
PIP3 is a regulator of cytoskeletal reorganization and cell motility
[39]. We therefore studied whether the deﬁcit of PTEN could modify
endothelial cell migration, in a wound scratch assay. As shown inFig. 6A, siRNA-mediated PTEN knock-down markedly suppressed di-
rectional migration of endothelial cells.
Increases in intracellular PIP3 may stimulate F-actin polarization
[40], and we therefore tested whether PTEN knockdown would affect
actin polymerization in endothelial cells. We used cellular imaging
approaches to analyze the effects of siRNA-mediated PTEN knock-
down on actin cytoskeleton structure, using phalloidin to label F
actin in these cells. As shown in Fig. 6B, siRNA-mediated PTEN knock-
down led to a marked increase in actin polymerization compared
with cells transfected with control siRNA. We next studied the effects
of PTEN knockdown on activation of the small GTPase Rac1, a mem-
ber of the Rho GTPase family that has been implicated in cortical
actin ﬁlament reorganization [41,42] and Akt phosphorylation [26],
as well as in ADP-mediated eNOS activation [3]. Rac1 activity was an-
alyzed in live cells using a Rac1 FRET biosensor [29]. Endothelial cells
were co-transfected with the Rac1 biosensor plus either control or
PTEN siRNA, and then stimulated with ADP and imaged in real time.
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blocked following siRNA-mediated PTEN-knockdown.
4. Discussion
These studies have explored the role of the lipid–protein phospha-
tase PTEN in ADP-modulated regulation of eNOS and related signaling
pathways in vascular endothelial cells. Although the involvement of
PTEN in eNOS regulation has been recently characterized [12], the
present studies provide novel information on the role of the purine nu-
cleotide ADP in this signaling pathway. The present study, uses physio-
logical ADP concentrations [3,43,44], to show that ADP is able toFig. 4. siRNA-mediated “double knockdown” of p38 MAPK and PTEN. Endothelial cells were
p38 MAPK targeting constructs as indicated; for each experiment the balance was made up
lowing transfection, endothelial cells were treated with ADP (25 μM) and analyzed in eNOS
B, endothelial cells transfected with control or p38 MAPK siRNA targeting constructs were
immunoblots as shown. Panel C shows the effect on eNOS activity of the siRNA mediated dou
was used. The results shown for the activity assays represent data pooled from 3 experimen
dependent experiments with equivalent results. * indicates p b 0.05.promote the dynamic phosphorylation of PTEN in vascular endothelial
cells (Fig. 1). One principal enzymatic activity of PTEN is the dephos-
phorylation of the signaling phospholipid PIP3, forming PIP2; the
resulting depletion of PIP3 levels serves to inhibit activation of the
phospholipid-dependent kinase-1 (PDK1), thereby attenuating the
PI3K/Akt pathway. Phosphorylation of PTEN is associatedwith inactiva-
tion of its lipid phosphatase activity as a consequence of the phos-
phoenzyme's translocation away from the plasma membrane, where
the enzyme's hydrophobic lipid substrates are sequestered [9]. Con-
versely, phosphorylated PTEN is sequestered in the cytosol, where the
phospho-enzyme apparently may still exert its phosphoprotein phos-
phatase activity despite its lack of access to lipid substrates in the celltransfected at a ﬁnal siRNA concentration of 60 nM, comprised of 30 nM PTEN and/or
by control siRNA to yield a ﬁnal concentration of 60 nM for all experiments. 48 h fol-
activity assays or in immunoblots probed with antibodies as shown (panel A). In Panel
treated with ADP (25 μM) for the indicated times, and then probed with antibodies in
ble knockdown of Akt and PTEN. For each condition siRNA ﬁnal concentration of 60 nM
ts, each performed in duplicate. The immunoblot shown is representative of three in-
2592 R. Bretón-Romero et al. / Biochimica et Biophysica Acta 1833 (2013) 2586–2595membrane [15]. PTEN is a critical negative regulator of the PI3K/Akt
pathway in several cell types [31,45–47], yet the enzyme also modu-
lates many other cellular responses independent of its effects on PI3K/
Akt [48]. Our new ﬁndings implicate PTEN in a broad range of endothe-
lial cell signaling responses involving eNOS.
We found that PTEN knockdown led to a marked increase in both
basal and ADP-dependent eNOS phosphorylation at its Ser1179 activa-
tion site, associated with an increase in the phosphorylation of kinase
Akt. Ser1179 is the most thoroughly studied eNOS phosphorylation
site, and has been shown to be phosphorylated not only by kinase
Akt, but also by AMPK, PKG, PKA, among other protein kinases [49].Fig. 5. Analyses of PIP3 metabolism in endothelial cells following siRNA-mediated PTEN
harvested and lysed, and total cellular PIP3 levels were measured in a dot-blot assay that
anti-GST antibody, as described in the text. A representative dot-blot is shown, as well as a
* indicates p b 0.05. Panel B shows representative images of endothelial cells transfected w
with ADP and analyzed for PIP3-accumulation by FRET microscopy in live cells for 60 min. P
were normalized to the basal CFP/YFP ratio at t = 0 min. The bar graph represents the mea
cumulation at the plasma membrane in control vs. PTEN siRNA-transfected cells. ** indicatMoreover, numerous distinct protein kinases have been found to phos-
phorylate eNOS at other serine, threonine, and tyrosine residues in the
protein. Despite a central role for PTEN in modulating PI3K/Akt re-
sponses, we have previously shown that the inhibition of the PI3K/Akt
pathway does not affect ADP-promoted eNOS phosphorylation [3].
Since PTEN may modulate a broad range of PI3K/Akt-independent sig-
naling pathways in different cell types, the enhancement of eNOS phos-
phorylation following PTEN knockdown most plausibly reﬂects the
effects of PTEN on a phosphorylation pathway distinct from PI3K/Akt.
Indeed, PTEN has an established role as a phosphoprotein phosphatase,
and the phosphoprotein phosphatase substrates for PTEN includeknockdown. Panel A, endothelial cells transfected with control or PTEN siRNA were
was probed with a GST-tagged PIP3-Grip construct, which was then developed with
bar graph showing pooled data from three experiments, each performed in triplicate.
ith PIP3 biosensor into control or PTEN siRNA-transfected cells. Cells were then treated
anel C, tracings shown are representative of three independent experiments. FRET data
n values ± s.e.m. of three independent experiments analyzing ADP-stimulated PIP3 ac-
es p b 0.01.
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study, we found that ADP promotes the robust phosphorylation of
p38 MAPK, and we also found that ADP-promoted p38 MAPK phos-
phorylation was signiﬁcantly increased after siRNA-mediated PTEN
knockdown (Fig. 1 and 2). The fact that basal eNOS activity increasesFig. 6. PTEN modulates actin organization and Rac1 activity in endothelial cells. Cell migratio
scratch in endothelial cells transfected with either control or PTEN siRNA. Pooled data of the
(Panel A). Panel B, confocal micrographic images of endothelial cells that were transfected wit
in the left panels or with vinculin antibodies to show focal adhesion contacts (green) in the
actin and vinculin staining in yellow. Panel C shows the results of a Rac1 activity assay analyze
co-transfected with a FRET-based active Rac1 biosensor, and then treated with ADP or vehicle
text. The FRET valueswere normalized to the basal CFP/YFP ratio at 0 min; a representative exp
experiments analyzing Rac1 activity in control vs. PTEN siRNA-transfected cells after stimulatifollowing PTEN knockdownmay suggest a role for PTEN in the mainte-
nance of basal vascular tone, yet the fact that ADP treatment further
augments eNOS phosphorylation and activation suggests that ADP-
mediated eNOS activation also is modulated by PTEN. Our studies
provide evidence indicating that the inhibition of PTEN may be an was recorded by phase contrast microscopy over a 20 h time course following wound
wound recovery from three independent experiments is quantiﬁed as a function of time
h control or PTEN siRNA, and then ﬁxed and stained with phalloidin to reveal actin (red)
middle panels; the merged images in the right-hand panels show the overlap between
d using a FRET-based Rac1 biosensor. Cells transfected with control or PTEN siRNA were
. FRET was recorded in live cells for 60 min following ADP treatment, as described in the
eriment is shown. The bar graph represents themean values ± SEM of three independent
on with ADP for 40 min. *** indicates p b 0.0001.
Fig. 7. Proposed model for the role of PTEN in ADP-dependent nitric oxide production.
This ﬁgure shows a model portraying some of the key interactions between signaling
pathways that are modulated by ADP and lead to the activation of eNOS and the pro-
duction of nitric oxide. Activation by extracellular ADP of cell surface P2Y1 receptors
leads to the phosphorylation and subsequent inactivation of PTEN in endothelial
cells, which in turn attenuates PTEN-catalyzed PIP3 hydrolysis and thereby increases
intracellular PIP3. The resulting increase in PIP3 levels leads to the activation of kinases
Akt and p38 MAPK and promotes eNOS and Rac1 activation.
2594 R. Bretón-Romero et al. / Biochimica et Biophysica Acta 1833 (2013) 2586–2595determinant of eNOS-dependent endothelium relaxation responses [50].
p38MAPK and eNOS crosstalk have been previously observed in various
endothelial models [24]. The current studies have established that
ADP-stimulated eNOS activation is markedly attenuated by the inhibi-
tion of p38 MAPK. These ﬁndings support a model in which p38 MAPK
acts as a key modulator of ADP signaling to eNOS (Fig. 3). Our “double
knockdown” experiments targeting both p38MAPK and PTEN (Fig. 4) in-
dicated that the increased eNOS activation promoted by siRNA-mediated
PTEN knockdownwas blocked by also knocking down p38MAPK. Taken
together, these ﬁndings suggest that ADP-promoted NO production is
enhanced by PTEN phosphorylation and inactivation, which then per-
mits the sequential activation of p38 MAPK and NOS in endothelial
cells. From the pathophysiological point of view, it is enticing to suggest
that a feedback loop may exist between platelet-derived ADP and
endothelium-derived nitric oxide that modulates the prothrombotic/
proinﬂammatory consequences of platelet aggregation. Indeed, ADP re-
leased by platelets may interact with endothelial P2Y1 receptors and in-
activate PTEN leading to eNOS activation and NO synthesis with
subsequent inhibition of platelet aggregation. Thesemay have important
clinical implications when considering the effects of ADP receptor antag-
onists in the treatment of cardiovascular events.
A key enzymatic activity of PTEN is its role as a lipid phosphatase
able to catalyze dephosphorylation of PIP3 to PIP2 [51,52]. As expected,
we found that PTEN knockdown yielded a marked increase in steady
state PIP3 levels in endothelial cells (Fig. 5A). Analyses in living cells re-
vealed that ADP-dependent increases in PIP3 were no longer seen fol-
lowing siRNA-mediated PTEN knockdown, consistent with our ﬁnding
that ADP promotes PTEN inhibition, such that when PTEN is knocked
down, further ADP-stimulated PTEN-mediated PIP3 response is no
longer observed (Fig. 5B). Through its role in phosphatidylinositol ho-
meostasis, PTEN has been described to be implicated in cell polarity
and migration, leading to cytoskeleton reorganization [53,39]. siRNA-
mediated PTEN knockdownmarkedly suppressed directionalmigration
of endothelial cells, while PIP3 increase into the cells is enough to stim-
ulate polarized accumulation of F-actin [40] (Fig. 6). Upon PTEN inhibi-
tion, PIP3 accumulates and promotes the activation of a subset of
proteins involved in actin remodeling and cell motility, including Rac1
[13,14,54,55]. We analyzed Rac1 activity in living cells using a Rac1
FRET biosensor, and found that Rac1 activation in response to ADP
was decreased following siRNA-mediated PTEN. These results implicate
PTEN inactivation in the pathway leading from ADP receptor stimula-
tion to activation of Rac1.
5. Conclusion
These studies demonstrate a role for PTEN in ADP receptor-
dependent eNOS activation. Our results support a model (Fig. 7) in
which ADP promotes the transient phosphorylation and inactivation
of PTEN, leading to an increase in PIP3 levels, which then triggers
the activation of PI3K/Akt, p38 MAPK, and an enhanced eNOS activity.
Furthermore we establish PTEN and PIP3 levels as critical mediators
for Rac1 activation and ADP-induced cell migration. These studies
add new insight into the response of the endothelium to extracellular
ADP, potentially identifying novel targets for the pharmacological
regulation of NO signaling.
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